ICD-10 2025: Know What 2025 Has in Store for Oncology ICD-10 Coding

Why This Topic Matters

The changes discussed affect diagnosis specificity, oncology reporting, and Medicare Advantage risk adjustment. Understanding the update helps coding and documentation teams prepare for the new reporting period and related billing impacts.

Article Sections

1. Introduction and Medicare billing context

   Introduces the scope of the 2025 ICD-10 update and its relevance to oncology coding and Medicare billing. It also frames the discussion around CMS changes and risk adjustment.

2. Hodgkin and follicular lymphoma remission additions

   Covers expansions within major lymphoma categories that add remission-related diagnosis options. The section focuses on how the update broadens specificity within these groups.

3. New remission status codes for other lymphomas

   Discusses additional lymphoma group updates that include remission-related status reporting. It also notes the broader expansion across several lymphoma families.

4. New condition codes

   Summarizes newly added diagnosis codes that further distinguish certain lymphoma presentations. The section explains that the update adds more granular condition reporting.

5. Estrogen receptor status code overhaul

   Reviews a major revision to the receptor-status category for oncology reporting. It describes the expansion of status distinctions tied to hormone and growth factor receptors.

6. Significance of the change

   Explains the broader impact of the update on documentation specificity, CDI, and Medicare Advantage risk adjustment. It also places the changes in the context of CMS reporting requirements.